webinar register page

Webinar banner
Single-cell mutational profiling enhances the clinical evaluation of AML MRD
Early detection of Minimal Residual Disease (MRD) detection holds great promise for patient therapy selection. Ongoing clinical trials indicate mutations detected early on, offer better patient stratification and treatment options which may prevent relapse.

Dr. Asiri Ediriwickrema from the Majeti lab at Stanford University, will discuss his recent publication in Blood Advances and the promise of single-cell DNA sequencing technology for MRD detection in hematological malignancies.

Jul 21, 2020 06:30 PM in Madrid

Webinar logo
Webinar is over, you cannot register now. If you have any questions, please contact Webinar host: Mission Bio Marketing.